Literature DB >> 8908164

Clear cell sarcoma of tendons and aponeuroses with t(12;22) (q13;q12) diagnosed initially as malignant melanoma.

B Nedoszytko1, K Mrózek, A Roszkiewicz, A Kopacz, M Swierblewski, J Limon.   

Abstract

Cytogenetic analysis performed on a specimen from an inguinal lymph node metastasis of a tumor diagnosed initially as a cutaneous malignant melanoma revealed the following karyotype: 50,XX, +2, +7, +8, +8, t(12;22) (q13;q12). The finding of t(12;22) (q13;q12), an abnormality specific of clear cell sarcoma of tendons and aponeuroses (CCS), prompted reanalysis of histologic slides, and a final diagnosis of CCS was made. Our case illustrates the usefulness of cytogenetic analysis in the differential diagnosis of CCS and malignant melanoma. In addition, extra copies of chromosomes 8, 7, and 2, present in our case as well as in previously reported tumors, seem to play an important, although at present not understood, role in the development of CCS.

Entities:  

Mesh:

Year:  1996        PMID: 8908164     DOI: 10.1016/s0165-4608(96)00113-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Clear cell sarcoma of the scapula. A case report and review of the literature.

Authors:  Constantinos J Kazakos; Vasilios G Galanis; Alexandra Giatromanolaki; Dennis-Alexander J Verettas; Efthimios Sivridis
Journal:  World J Surg Oncol       Date:  2006-08-07       Impact factor: 2.754

2.  Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts).

Authors:  S M Langezaal; J F Graadt van Roggen; A M Cleton-Jansen; J J Baelde; P C Hogendoorn
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

3.  Primary clear cell sarcoma of the femur: a unique case with RT-PCR and direct sequencing confirmation of EWSR1/ATF1 fusion gene.

Authors:  Yuta Kubota; Kazuhiro Tanaka; Masanori Hisaoka; Tsutomu Daa; Tatsuya Iwasaki; Masanori Kawano; Ichiro Itonaga; Hiroshi Tsumura
Journal:  BMC Musculoskelet Disord       Date:  2021-01-21       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.